In many pharmaceutical companies, employees record their manufacturing actions on paper with handwritten signatures, which creates risks and inefficiencies. It is possible to digitize these processes in a simple way and add the security of the biometric electronic signature.

In many pharmaceutical companies, employees still record manufacturing control data on paper and authenticate it with their handwritten signature. This can lead to inefficiencies and errors that jeopardize data integrity.

The use of biometrics in electronic signatures solves all the current problems with passwords in GMP regulated pharmaceutical manufacturing environments. But what technologies should we use? How should they be applied?

The use of the biometric electronic signature not only ensures data integrity and compliance with pharmaceutical regulations, but also solves the problems of inconvenience and loss of time and efficiency of employees.

Password-based electronic signatures are widely used in manufacturing software (MES, ERP) in the pharmaceutical industry, putting at risk data integrity and regulatory compliance. The solution is the biometric electronic signature.

The ALCOA+ requirements defined by the FDA establish, among others, the characteristics for correct identification of employees in regulated pharmaceutical processes. The use of biometrics solves the current difficulties in meeting them.

Current employee identification methods in pharmaceutical manufacturing processes cause data integrity breaches in GMP regulated environments, which can be solved with biometrics.